Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.
Kuehn JC, Metzger P, Neidert N, Matysiak U, Gräßel L, Philipp U, Bleul S, Pauli T, Falkenstein J, Bertemes H, Cysar S, Hess ME, Frey AV, Duque-Afonso J, Schorb E, Machein M, Beck J, Schnell O, von Bubnoff N, Illert AL, Peters C, Brummer T, Prinz M, Miething C, Becker H, Lassmann S, Werner M, Börries M, Duyster J, Heiland DH, Sankowski R, Scherer F. Kuehn JC, et al. Among authors: falkenstein j. NPJ Precis Oncol. 2024 Aug 14;8(1):180. doi: 10.1038/s41698-024-00674-y. NPJ Precis Oncol. 2024. PMID: 39143272 Free PMC article.
Diya - A universal light illumination platform for multiwell plate cultures.
Kumar S, Anastassov S, Aoki SK, Falkenstein J, Chang CH, Frei T, Buchmann P, Argast P, Khammash M. Kumar S, et al. Among authors: falkenstein j. iScience. 2023 Sep 9;26(10):107862. doi: 10.1016/j.isci.2023.107862. eCollection 2023 Oct 20. iScience. 2023. PMID: 37810238 Free PMC article.
Cell-intrinsic ceramides determine T cell function during melanoma progression.
Hose M, Günther A, Naser E, Schumacher F, Schönberger T, Falkenstein J, Papadamakis A, Kleuser B, Becker KA, Gulbins E, Haimovitz-Friedman A, Buer J, Westendorf AM, Hansen W. Hose M, et al. Among authors: falkenstein j. Elife. 2022 Nov 25;11:e83073. doi: 10.7554/eLife.83073. Elife. 2022. PMID: 36426850 Free PMC article.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Vehling-Kaiser U, Sent D, Klare P, Hagen V, Chiabudini M, Falkenstein J, Indorf M, Runkel E, Potthoff K. Decker T, et al. Among authors: falkenstein j. BMC Cancer. 2020 Apr 6;20(1):286. doi: 10.1186/s12885-020-06747-y. BMC Cancer. 2020. PMID: 32252684 Free PMC article. Clinical Trial.